生物银行：心力衰竭管理中的未满足需求。

Biobanks: The unmet need in heart failure management.

机构信息

Department of Clinical, Anesthesiological and Cardiovascular Sciences, Sapienza University of Rome, Viale del Policlinico, 155, Rome 00161, Italy.

Clinical Research Unit, AOU Policlinico Umberto I- Sapienza University of Rome, Viale del Policlinico, 155, Rome 00161, Italy.

出版信息

Vascul Pharmacol. 2023 Jun;150:107179. doi: 10.1016/j.vph.2023.107179. Epub 2023 Apr 28.

DOI:10.1016/j.vph.2023.107179

PMID:37121386

Abstract

Heart failure (HF) represents a major health and economic issue, with increasing morbidity and mortality in spite of novel therapeutic weapons. The disappointing results of HF management may be due to the current therapeutic approach based on the paradigm "one fits all", that cannot apply to a complex and multifaceted syndrome as HF. At this regard, the European Union is developing policies to move from reductionism to precision medicine, in order to identify specific disease biomarkers and develop targeted therapeutic strategies. The institution of biobanks may represent the game changer in HF scenario, providing a collection of human biological materials with the related medical and epidemiological data fueling the development of personalized therapeutic approach and fostering current and/or future research projects.

摘要

心力衰竭（HF）是一个主要的健康和经济问题，尽管有新的治疗手段，但发病率和死亡率仍在上升。HF 管理的结果令人失望，可能是由于目前基于“一刀切”范式的治疗方法，这种方法不适用于 HF 这样复杂和多方面的综合征。在这方面，欧盟正在制定政策，从还原论转向精准医学，以确定特定的疾病生物标志物，并开发靶向治疗策略。生物银行的建立可能会改变 HF 领域的游戏规则，提供一系列人类生物材料，并附有相关的医学和流行病学数据，为个性化治疗方法的发展提供动力，并促进当前和/或未来的研究项目。